James Shayman, MD, Nephrology, Ann Arbor, MI, Michigan Medicine

JamesAShaymanMD

Nephrology Ann Arbor, MI

Physician

Dr. Shayman is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shayman's full profile

Already have an account?

  • Office

    1500 East Medical Center Dr
    University Hospital - Im Nephrology Inpatient
    Ann Arbor, MI 48109
    Phone(734) 888-2871
  • Is this information wrong?

Education & Training

  • Washington University - Barnes-Jewish Hospital
    Washington University - Barnes-Jewish HospitalFellowship, Nephrology, 1985 - 1985
  • Washington University - Barnes-Jewish Hospital
    Washington University - Barnes-Jewish HospitalFellowship, Nephrology, 1983 - 1984
  • Washington University - Barnes-Jewish Hospital
    Washington University - Barnes-Jewish HospitalResidency, Internal Medicine, 1980 - 1983
  • Washington University School of Medicine in St. Louis
    Washington University School of Medicine in St. LouisClass of 1980

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1986 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1994
  • Fellow (ASNF) American Society of Nephrology

Publications & Presentations

PubMed

Lectures

  • Entrepreneurship and Innovation in Kidney Care 
    American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/8/2019

Press Mentions

  • Sanofi Pivotal Trial to Target Driver of Cyst Growth in PKD
    Sanofi Pivotal Trial to Target Driver of Cyst Growth in PKDNovember 12th, 2018
  • Protalix’s Phase III Asset for Fabry Could Struggle to Demonstrate Superiority over Fabrazyme but Immunogenicity Benefits Support Regulatory Chances, Experts Say
    Protalix’s Phase III Asset for Fabry Could Struggle to Demonstrate Superiority over Fabrazyme but Immunogenicity Benefits Support Regulatory Chances, Experts SayFebruary 6th, 2021
  • Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis from the HALT-PKD Trials
    Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis from the HALT-PKD TrialsJanuary 4th, 2018

Grant Support

  • Lysosomal Phospholipase A2 In Autoimmune DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2012
  • The Pharmacological Treatment Of Fabry DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2012
  • The Pharmacologic Treatment Of Fabry DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2008
  • Glycosphingolipids In Diabetes MellitusNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1999
  • Glycosphingolipid And Renal CarcinomaNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
  • Sphingolipids And Polycystic Kidney DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1997
  • Renal Polyol MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1990–1994
  • Peptide Hormone Stimulated Inositol MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1989
  • Peptide Hormone Stimulated Inositol MetabolismNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985

Professional Memberships

Hospital Affiliations